ICPT Intercept Pharmaceuticals, Inc.

114.77
+4  (3%)
Previous Close 111.11
Open 111.81
Price To book 8.76
Market Cap 2.85B
Shares 24,831,000
Volume 393,624
Short Ratio 11.51
Av. Daily Volume 439,827

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved May 27 2016.
Obeticholic acid (OCA)
Primary biliary cirrhosis (PBC) - POISE
Enrollment of interim analysis to be completed mid-2017.
Obeticholic acid (OCA) - REGENERATE
Adult nonalcoholic steatohepatitis (NASH) patients.
Phase 2 data due 2017.
Obeticholic acid (OCA) AESOP
Primary Sclerosing Cholangitis (PSC)

Latest News

  1. Should Gilead Sciences Be Worried About Allergan?
  2. Intercept Announces New Ocaliva® (obeticholic acid) and INT-767 Data to be Presented at EASL 2017
  3. Big Opportunity in Liver Treatment for Intercept Pharmaceuticals
  4. ETFs with exposure to Intercept Pharmaceuticals, Inc. : April 7, 2017
  5. What Does Big Pharma Want To Buy? 3 Drugmakers On Merger Track
  6. Intercept to Present at Upcoming Conference
  7. These stocks are getting whacked after the GOP unveils its Obamacare replacement
  8. Morningstar Runs the Numbers
  9. Blog Coverage Intercept Pharmaceuticals Received NICE Approval for Ocaliva for Use in England, Wales and Northern Ireland
  10. NICE Recommends Ocaliva® (obeticholic acid) for the Treatment of Patients with Primary Biliary Cholangitis in England, Wales and Northern Ireland
  11. Intercept Pharmaceuticals, Inc. :ICPT-US: Earnings Analysis: 2016 By the Numbers : February 27, 2017
  12. Intercept (ICPT) Q4 Loss Wider than Expected, Revenues Beat
  13. Nasdaq Slips as Biotechnology Shares Decline
  14. Edited Transcript of ICPT earnings conference call or presentation 23-Feb-17 1:30pm GMT
  15. Intercept (ICPT) Reports a Wider Q4 Loss
  16. Intercept reports 4Q loss
  17. Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Business Update
  18. Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More
  19. Intercept (ICPT) to Post Q4 Earnings: What's in the Cards?